Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C23H38NO2.Na |
| Molecular Weight | 383.5431 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].CCCCCCCCCCCCCCCCNC1=CC=C(C=C1)C([O-])=O
InChI
InChIKey=RIEGDRWQKNITRV-UHFFFAOYSA-M
InChI=1S/C23H39NO2.Na/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-20-24-22-18-16-21(17-19-22)23(25)26;/h16-19,24H,2-15,20H2,1H3,(H,25,26);/q;+1/p-1
| Molecular Formula | C23H38NO2 |
| Molecular Weight | 360.5533 |
| Charge | -1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | Na |
| Molecular Weight | 22.9898 |
| Charge | 1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Cetaben has been identified as an anti-atherosclerotic hypolipidaemic
substance. Cetaben is a unique, PPARα-independent peroxisome proliferator with hypolipidemic activity that inhibits cholesterol synthesis in the human hepatoma Hep-G2 cells resulting in reversible changes in Golgi morphology. Cetaben represents an exceptional type of peroxisome proliferator, specifically affecting peroxisomes, without having a negative influence on the processes of peroxisome biogenesis. Cetaben raised only the peroxisomal enzymes, acyl-CoA oxidase, glycerone-phosphate acyltransferase, D-amino-acid oxidase, catalase, and urate oxidase. Cetaben sodium has being shown to be an antiatherosclerotic agent.
Originator
Approval Year
Sample Use Guides
In Vivo Use Guide
Curator's Comment: Guinea pigs: cetaben (90 mg/kg/day, p.o.) inhibited the development of atherosclerotic lesions in guinea pigs fed a cholesterol and vitamin D2-rich diet. https://www.ncbi.nlm.nih.gov/pubmed/6604004
The effects of cetaben and clofibric acid were compared on the activities of peroxisomal enzymes in the liver and kidney of male Wistar rats. Cetaben at 200 mg/kg body wt increased the activities of all of the enzymes in the liver. The data obtained in the dose-response study of cetaben revealed a significant rise in the activities of peroxisomal enzymes in both the liver and kidney at doses of 50-100 mg/kg body wt administered over 10 days, but the maximal effect was observed at 250 mg/kg.
Route of Administration:
Oral
The activity of the peroxisomal bifunctional enzyme was not affected in HepG2 cells by clofibric acid and cetaben, whereas the mRNA level was elevated to 2.3 fold by 10 umol/l cetaben. At high concentrations of cetaben all enzyme activities were decreased in both cell lines due to its high cytotoxicity.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:23:52 GMT 2023
by
admin
on
Fri Dec 15 15:23:52 GMT 2023
|
| Record UNII |
433YPU24B8
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29703
Created by
admin on Fri Dec 15 15:23:52 GMT 2023 , Edited by admin on Fri Dec 15 15:23:52 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C72984
Created by
admin on Fri Dec 15 15:23:52 GMT 2023 , Edited by admin on Fri Dec 15 15:23:52 GMT 2023
|
PRIMARY | |||
|
DTXSID30214254
Created by
admin on Fri Dec 15 15:23:52 GMT 2023 , Edited by admin on Fri Dec 15 15:23:52 GMT 2023
|
PRIMARY | |||
|
CHEMBL31907
Created by
admin on Fri Dec 15 15:23:52 GMT 2023 , Edited by admin on Fri Dec 15 15:23:52 GMT 2023
|
PRIMARY | |||
|
23703815
Created by
admin on Fri Dec 15 15:23:52 GMT 2023 , Edited by admin on Fri Dec 15 15:23:52 GMT 2023
|
PRIMARY | |||
|
433YPU24B8
Created by
admin on Fri Dec 15 15:23:52 GMT 2023 , Edited by admin on Fri Dec 15 15:23:52 GMT 2023
|
PRIMARY | |||
|
64059-66-1
Created by
admin on Fri Dec 15 15:23:52 GMT 2023 , Edited by admin on Fri Dec 15 15:23:52 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |